Mortality Due to Hyperglycemic Crises in the US, 1999-2022

JAMA. 2024 Feb 6;331(5):440-442. doi: 10.1001/jama.2023.26174.

Authors

Matthew A Crane¹, Audrey Lam², Emil Ekanayake², Yazan Y Alshawkani¹, Colleen Christmas³, Alison Gemmill⁴, John A Romley²

Affiliations

¹ Department of Medicine, Johns Hopkins University, Baltimore, Maryland.
² USC Leonard D. Schaeffer Center for Health Policy and Economics, Los Angeles, California.
³ Division of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
⁴ Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

PMID: 38206620
PMCID: PMC10784995 (available on 2024-07-11)
DOI: 10.1001/jama.2023.26174

No abstract available

Plain language summary

This study analyzes trends in US mortality attributed to both diabetic ketoacidosis and hyperosmolar hyperglycemic state from 1999-2022.

MeSH terms

Diabetic Ketoacidosis* / epidemiology
Diabetic Ketoacidosis* / mortality
Humans
Hyperglycemic Hyperosmolar Nonketotic Coma* / epidemiology
Hyperglycemic Hyperosmolar Nonketotic Coma* / mortality
Insulin
United States / epidemiology

Substances

Insulin